Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc. (HALO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Halozyme is a biopharmaceutical company advancing drug delivery solutions, primarily through its ENHANZE technology (rHuPH20 enzyme) to facilitate subcutaneous delivery of biologics. The company also develops Hypercon and Surf Bio technologies for drug hyperconcentration and auto-injector devices. Key proprietary products include Hylenex and XYOSTED.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $480,999 | $325,719 | $857,707 | $590,580 |
| Net Income | $229,913 | $165,160 | $379,962 | $283,255 |
| Diluted EPS | $1.90 | $1.33 | $3.11 | $2.26 |
| Operating Cash Flow (6M) | $420,969 | $253,932 | - | - |
| Cash & Equivalents (End of Period) | $163,138 | - | - | - |
| Marketable Securities (End of Period) | $67,865 | - | - | - |
| Total Debt (Carrying Amount) | $2,146,654 | - | - | - |
Note: Q2 2025 comparative balance sheet data is not provided in the text; only income statement and cash flow comparisons are available.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 48% year-over-year (YoY) for Q2 2026 and 45% for the six-month period.
- Royalties: Increased 50% in Q2 (driven by VYVGART Hytrulo and DARZALEX SC) and 47% for six months.
- Product Sales: Increased 59% in Q2, primarily due to a 156% surge in bulk rHuPH20 sales and 19% growth in proprietary product sales (XYOSTED).
- Collaborative Agreements: Increased 13% in Q2 due to $35.5M in upfront license fees, offset by lower milestone revenue compared to the prior year.
- Expense Increases: Total operating expenses rose 57% in Q2 and 56% for six months.
- Cost of Sales: Increased 71% (Q2) due to higher bulk rHuPH20 volume.
- Amortization: Increased 66% (Q2) following the November 2025 acquisition of Elektrofi.
- R&D and SG&A: Increased 58% and 37% respectively, driven by acquisitions (Elektrofi and Surf Bio) and higher professional/consulting fees.
- Profitability: Net income grew 39% in Q2 and 34% for six months. Operating margins remained robust despite higher expenses.
- Debt Structure: The company issued $750M in 2031 Convertible Notes and $750M in 2032 Convertible Notes in late 2025. In Q2 2026, the company repurchased approximately $1.02B of its 2027 and 2028 Convertible Notes using proceeds from the new issuances.
Guidance, Outlook, and Risks
- Capital Return: In May 2026, the Board authorized a new $1.0 billion share repurchase program through December 31, 2028. The previous $750M program was completed in June 2026. In Q2 2026, the company repurchased 4.8 million shares for $332.7 million.
- Strategic Acquisitions: The company integrated Elektrofi (Hypercon technology) and Surf Bio (hyperconcentration technology) in late 2025, expanding its pipeline and collaboration opportunities.
- Key Partnerships: New collaborations announced in 2026 include Incyte (myeloproliferative neoplasms), GSK (oncology/ADCs), and Vertex (Hypercon technology). Existing partners like Janssen and argenx continue to drive royalty growth with new approvals and indications.
- Risks and Contingencies:
- Intangible Asset Impairment: A partner is evaluating the potential return of a target under the Elektrofi acquisition. A decision is expected by February 2027. If the target is returned without a replacement, it could trigger a material impairment charge to intangibles and goodwill.
- Regulatory/Pricing: Risks related to U.S. healthcare pricing reforms, including the Inflation Reduction Act (IRA) and potential Most Favored Nation (MFN) pricing policies, which could impact partner product revenues.
- Legal: The company is not currently a party to any material legal proceedings, though it faces general litigation risks common to the industry.
Investor Verification Checklist
- Elektrofi Target Decision: Monitor the February 2027 decision regarding the potential return of a target by an Elektrofi partner, which could impact goodwill and intangible asset valuations.
- Convertible Note Repurchases: Verify the final settlement of the $1.02B repurchase of 2027 and 2028 notes and the impact on future interest expense and dilution.
- Royalty Concentration: Assess the sustainability of royalty growth from top partners (Janssen, argenx) given the life-cycle stage of products like Herceptin and MabThera.
- Share Repurchase Execution: Track the pace of the new $1.0 billion buyback program relative to the company's cash flow generation.
- Regulatory Impact: Evaluate the potential impact of CMS final rules on fixed combination drugs (ENHANZE products) under the IRA for the 2029 price applicability year.